AZD1208 25 mg | 97.24%
TargetMol
AZD1208 is a novel, orally bioavailable, highly selective PIM kinase inhibitor with single nanomolar potency against all three PIM kinases.
More Information Supplier PageAZD1208
Search Results
4-Hydroxyantipyrine 200 mg | 99.37%
TargetMol
4-Hydroxyantipyrine is formed during oxidative deamination of aminopyrine.
More Information Supplier Page4-Hydroxyantipyrine
Pexidartinib 200 mg | 99.66%
TargetMol
Pexidartinib is a capsule formulation containing a small-molecule receptor tyrosine kinase (RTK) inhibitor of KIT, CSF1R and FLT3 with potential antineoplastic activity.
More Information Supplier PagePexidartinib
Rabeprazole sodium 25 mg | 99.36%
TargetMol
Rabeprazole sodium is a 4-(3-methoxypropoxy)-3-methylpyridinyl derivative of timoprazole that is used in the therapy of stomach ulcers and Zollinger-Ellison syndrome. The drug inhibits H(+)-K(+)-exchanging ATPase which is found in gastric parietal cells.
More Information Supplier PageRabeprazole sodium
Rabeprazole sodium 100 mg | 99.36%
TargetMol
Rabeprazole sodium is a 4-(3-methoxypropoxy)-3-methylpyridinyl derivative of timoprazole that is used in the therapy of stomach ulcers and Zollinger-Ellison syndrome. The drug inhibits H(+)-K(+)-exchanging ATPase which is found in gastric parietal cells.
More Information Supplier PageRabeprazole sodium
Rabeprazole sodium 200 mg | 99.36%
TargetMol
Rabeprazole sodium is a 4-(3-methoxypropoxy)-3-methylpyridinyl derivative of timoprazole that is used in the therapy of stomach ulcers and Zollinger-Ellison syndrome. The drug inhibits H(+)-K(+)-exchanging ATPase which is found in gastric parietal cells.
More Information Supplier PageRabeprazole sodium
Rabeprazole Sulfide 200 mg | 99.34%
TargetMol
Rabeprazole is an antiulcer drug in the class of proton pump inhibitors.
More Information Supplier PageRabeprazole Sulfide
4E1rcat 2 mg | 99.36%
TargetMol
4E1RCat is a dual inhibitor of eIF4E:eIF4 g and eIF4E:4E-BP1 interaction. And it inhibits the binding of eIF4 g to eIF4E with IC50 of 3.2 μM.
More Information Supplier Page4E1rcat
4E1rcat 25 mg | 99.36%
TargetMol
4E1RCat is a dual inhibitor of eIF4E:eIF4 g and eIF4E:4E-BP1 interaction. And it inhibits the binding of eIF4 g to eIF4E with IC50 of 3.2 μM.
More Information Supplier Page4E1rcat
4E1rcat 100 mg | 99.36%
TargetMol
4E1RCat is a dual inhibitor of eIF4E:eIF4 g and eIF4E:4E-BP1 interaction. And it inhibits the binding of eIF4 g to eIF4E with IC50 of 3.2 μM.
More Information Supplier Page4E1rcat